Confluence Pharmaceuticals

Series-B
confluencepharma.com Biotech & Healthcare
Total Funding Undisclosed
Latest Round Undisclosed Series-B
Last Announced Jun 17, 2022
Investors Undisclosed
Decision Makers 4 Available

About Confluence Pharmaceuticals

Confluence Pharmaceuticals develops novel treatments for core social and communication impairments in Autism, Fragile X Syndrome, and related disorders.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B
Global Headquarters Undisclosed
Tracked Since Nov 8, 2026

Web & Domain Identity

Official Website confluencepharma.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

1 Events
  1. Capital Raise

    Raised undisclosed · Series-B

    fundraisingfox.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Confluence Pharmaceuticals.

Funding History

1 Round
Series-B equity · Jun 17, 2022

Founders & Leadership

2

Boyd W. Sturdevant

Chairman & Founder

Work email & phone locked Unlock →

Steven L. Johns

President & Founder

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

Recently funded startups
New SaaS launches
Never pay twice for contacts